A detailed history of Woodline Partners LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 188,564 shares of APLS stock, worth $5.29 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
188,564
Previous 187,000 0.84%
Holding current value
$5.29 Million
Previous $7.17 Million 24.19%
% of portfolio
0.05%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $45,105 - $64,358
1,564 Added 0.84%
188,564 $5.44 Million
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $76 - $119
2 Added 0.0%
187,000 $7.17 Million
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $42,871 - $56,091
774 Added 0.42%
186,998 $11 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $6.92 Million - $12.1 Million
186,224 New
186,224 $11.1 Million
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $3.05 Million - $4.31 Million
70,651 New
70,651 $3.65 Million
Q1 2022

May 16, 2022

SELL
$35.46 - $54.12 $1.46 Million - $2.23 Million
-41,199 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $2.06 Million - $3.29 Million
-66,877 Reduced 61.88%
41,199 $1.95 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $3.39 Million - $7.55 Million
108,076 New
108,076 $3.56 Million
Q2 2021

Aug 16, 2021

SELL
$40.9 - $64.9 $7.01 Million - $11.1 Million
-171,419 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$40.8 - $57.39 $6.99 Million - $9.84 Million
171,419 New
171,419 $7.36 Million
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $5.58 Million - $8.66 Million
-224,948 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $1.65 Million - $4.08 Million
92,001 Added 69.2%
224,948 $6.03 Million
Q4 2019

Feb 14, 2020

BUY
$22.1 - $30.8 $2.94 Million - $4.09 Million
132,947 New
132,947 $4.07 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.08B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.